mRNA-3705 MMA Study
Contact
Description
Eligibility and criteria
IRB Number:
22-020081
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
What to expect
- Receive a study drug via an intravenous (IV) infusion.
- Stay inpatient to monitor reaction to study drug.
- Have research checkups that include testing, blood draws, interviews, and questionnaires.
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.